List view / Grid view
30 June 2016 | By Victoria White, Digital Content Producer
The urological cancers market will increase from $17.9 billion in 2015 to $35.9 billion by 2022, according to business intelligence provider GBI Research...
29 June 2016 | By Victoria White, Digital Content Producer
Results from the Phase III RESORCE trial investigating Bayer’s regorafenib in patients with unresectable hepatocellular carcinoma have been announced...
28 June 2016 | By Victoria White, Digital Content Producer
The collaboration includes XmAb Bispecific Technology for 4 Novartis targets and access to Xencor Fc Technologies...
24 June 2016 | By Victoria White, Digital Content Producer
Some cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at a higher-than-normal risk of developing autoimmune diseases...
22 June 2016 | By Victoria White, Digital Content Producer
The open-label, dose-escalation portion of the trial will evaluate the safety and tolerability of INCAGN1876 in patients with solid tumours...
20 June 2016 | By Victoria White, Digital Content Producer
Researchers have discovered that an existing medication, denosumab, may prevent breast cancer in women carrying a faulty BRCA1 gene...
15 June 2016 | By Victoria White, Digital Content Producer
A study has found that women with ovarian cancer may benefit more from immunotherapy drug treatments if they are given straight after chemotherapy...
14 June 2016 | By Victoria White, Digital Content Producer
The launch of Roche’s Tecentriq will usher in a dramatic change in the treatment paradigm of bladder cancer, according to an analyst with GlobalData...
7 June 2016 | By Victoria White, Digital Content Producer
Using next-generation sequencing technology, researchers were able to study the genome of cancer cells, which is how they discovered the new cancer types...
7 June 2016 | By Victoria White, Digital Content Producer
BMS and MD Anderson are to collaborate to evaluate innovative strategies for the use of Opdivo and Yervoy to treat lung cancer patients...
7 June 2016 | By Victoria White, Digital Content Producer
Aprea presented clinical data from the Phase Ib part of the ongoing PiSARRO Phase Ib/II trial of APR-246 at the ASCO annual meeting...
7 June 2016 | By Victoria White, Digital Content Producer
Novartis has announced new data for the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in non-small cell lung cancer (NSCLC) and melanoma...
6 June 2016 | By Victoria White, Digital Content Producer
Keytruda is a humanised monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells...
6 June 2016 | By Victoria White, Digital Content Producer
Ganymed announced data from its randomised Phase II clinical study of IMAB362 in first-line treatment of gastric cancer at the ASCO 2016 Annual Meeting...
6 June 2016 | By Victoria White, Digital Content Producer
Data were presented from two early-phase trials evaluating Lilly's Alimta and Cyramza in combination with Merck's Keytruda in patients with NSCLC...
